소아 기면증의 진단과 치료
Pediatric Narcolepsy - Diagnosis and Treatment
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Narcolepsy is chronic devastating disease that characterized by excessive daytime sleepiness, cataplexy, which often precipitated by intense emotion or excitement, hypnagogic, or hypnapompic hallucinations, sleep paralysis and nocturnal disrupted sleep. In child onset narcolepsy, the presentations of narcolepsy can be very variable, making misdiagnosis as seizure disorders or delaying diagnosis as much as several years after disease onset. For the diagnosis of narcolepsy, overnight polysomnography(PSG) and multiple sleep latency test(MSLT) should be evaluated. Test for Cerebrospinal fluid hypocretin(orexin) concentration and human leukocyte antigens(HLA) would be great helpful to confirm the narcolepsy with cataplexy even in early stage of disease in children. The mainstays of treatment are that reducing the excessive daytime sleepiness, preventing the intrusion of the REM related phenomena including cataplexy and consolidating the nighttime sleep. Central nervous system stimulators such as methylphenidate or amphetamine decrease excessive daytime sleepiness and tricyclic antidepressant(TCA) or selective serotonin reuptake inhibitors(SSRI) can prevent cataplexy. Recently, new therapeutic agents such as modafinil and sodium oxybate are emerging in clinical practice with much effectiveness. Counseling for poor school performance, social isolation and depression should be provided. Early diagnosis and treatment can greatly improve the quality of life. Awareness of excessive daytime sleepiness in children or adolescent will allow pediatricians to effectively identify hypersomnia such as narcolepsy.
Abstract
Narcolepsy is chronic devastating disease that characterized by excessive daytime sleepiness, cataplexy, which often precipitated by intense emotion or excitement, hypnagogic, or hypnapompic hallucinations, sleep paralysis and nocturnal disrupted sleep. In child onset narcolepsy, the presentations of narcolepsy can be very variable, making misdiagnosis as seizure disorders or delaying diagnosis as much as several years after disease onset. For the diagnosis of narcolepsy, overnight polysomnography(PSG) and multiple sleep latency test(MSLT) should be evaluated. Test for Cerebrospinal fluid hypocretin(orexin) concentration and human leukocyte antigens(HLA) would be great helpful to confirm the narcolepsy with cataplexy even in early stage of disease in children. The mainstays of treatment are that reducing the excessive daytime sleepiness, preventing the intrusion of the REM related phenomena including cataplexy and consolidating the nighttime sleep. Central nervous system stimulators such as methylphenidate or amphetamine decrease excessive daytime sleepiness and tricyclic antidepressant(TCA) or selective serotonin reuptake inhibitors(SSRI) can prevent cataplexy. Recently, new therapeutic agents such as modafinil and sodium oxybate are emerging in clinical practice with much effectiveness. Counseling for poor school performance, social isolation and depression should be provided. Early diagnosis and treatment can greatly improve the quality of life. Awareness of excessive daytime sleepiness in children or adolescent will allow pediatricians to effectively identify hypersomnia such as narcolepsy.
참고문헌 (50)
- Medicine AAoS., "International Classification of Sleep Disorders" (2005), Diagnostic and coding manual
- Wise MS., "Narcolepsy in children", Semin Pediatr Neurol, 8, pp.198~206 (2001)
- Serra L., "Cataplexy features in childhood narcolepsy", Mov Disord, 23, pp.858~865 (2008)
- Nishino S., "Clinical and neurobiological aspects of narcolepsy", Sleep Med, 8, pp.373~399 (2007)
- Stores G., "The protean manifestations of childhood narcolepsy and their misinterpretation", Dev Med Child Neurol, 48, pp.307~310 (2006)
- Thorpy M., "Current concepts in the etiology, diagnosis and treatment of narcolepsy", Sleep Med, 2, pp.5~17 (2001)
- Guilleminault C., "Narcolepsy: diagnosis and management in :Principles and practice of sleep medicine", pp.2005, Elsevier
- Overeem S., "Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives", J Clin Neurophysiol, 18, pp.78~105 (2001)
- Vendrame M., "Narcolepsy in children: a single-center clinical experience", Pediatr Neurol, 28, pp.314~320 (2008)
- Nevsimalova S., "REM behavior disorder (RBD) can be one of the first symptoms of childhood narcolepsy", Sleep Med, 8, pp.784~786 (2007)
- Gagnon JF., "Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases", Lancet Neurol, 5, pp.424~432 (2006)
- Mosko SS., "Nocturnal REM latency and sleep disturbance in narcolepsy", Sleep, 7, pp.115~125 (1984)
- Mignot E., "and familial aspects of narcolepsy", Neurology, 50, pp.S16~S22 (1998)
- Han F., "Childhood narcolepsy in North China", Sleep, 24, pp.321~324 (2001)
- Silber MH., "The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study", Sleep, 25, pp.197~202 (2002)
- Okun ML., "Clinical aspects of narcolepsy-cataplexy across ethnic groups", Sleep, 25, pp.27~35 (2002)
- Dauvilliers Y., "Age at onset of narcolepsy in two large populations of patients in France and Quebec", Neurology, 57, pp.2029~2033 (2001)
- Nishino S., "Hypocretin (orexin) deficiency in human narcolepsy", Lancet, 355, pp.39~40 (2000)
- Sutcliffe JG., "The hypocretins: excitatory neuromodulatory peptides for multiple homeostatic systems, including sleep and feeding", Neurosci Res, 62, pp.161~168 (2000)
- Sakurai T., "Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior", Cell, 92, pp.573~585 (1998)
- Peyron C., "Neurons containing hypocretin (orexin) project to multiple neuronal systems", J Neurosci, 18, pp.9996~10015 (1998)
- Willie JT., "To eat or to sleep? Orexin in the regulation of feeding and wakefulness", Annu Rev Neurosci, 24, pp.429~458 (2001)
- Taheri S., "The role of hypocretins (orexins) in sleep regulation and narcolepsy", Annu Rev Neurosci, 25, pp.283~313 (2002)
- Lin L., "The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene", Cell, 98, pp.365~376
- Chemelli RM., "Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation", Cell, 98, pp.437~451 (1999)
- Nishino S., "Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy", Ann Neurol, 50, pp.381~388 (2001)
- Mignot E., "The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias", Arch Neurol, 59, pp.1553~1562 (2002)
- Dauvilliers Y., "CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions", J Neurol Neurosurg Psychiatry, 74, pp.1667~1673 (2003)
- Mignot E., "Sleep, sleep disorders and hypocretin (orexin)", Sleep Med, 5(1), pp.S2~S8 (2004)
- Peyron C., "A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains", Nat Med, 6, pp.991~997 (2000)
- Dauvilliers Y., "Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset", Ann Neurol, 56, pp.905~908 (2004)
- Black JL., "Search for neuron-specific and nonneuron- specific antibodies in narcoleptic patients with and without HLA DQB1*0602", Sleep, 25, pp.719~723 (2000)
- Mignot E., "Genetics of narcolepsy and other sleep disorders", Am J Hum Genet, 60, pp.1289~1302 (1997)
- Nishino S., "Narcolepsy: genetic predisposition and neuropharmacological mechanisms", Sleep Med Rev, 4, pp.57~599 (2000)
- Maret S., "Genetics of narcolepsy and other major sleep disorders", Swiss Med Wkly, 135, pp.662~665 (2005)
- Littner MR., "Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test", Sleep, 28, pp.113~121 (2005)
- Arand D., "The clinical use of the MSLT and MWT", Sleep, 28, pp.123~144 (2005)
- Aldrich MS., "Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy", Sleep, 20, pp.620~629 (1997)
- Challamel MJ., "Narcolepsy in children", Sleep, 17, pp.S17~S20 (1994)
- Nishino S., "Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin", orexin system, 2005, pp.9, 269~310
- Guilleminault C., "Excessive daytime sleepiness: a challenge for the practising neurologist", Brain, 124, pp.1482~1491 (2001)
- Broughton R., "Life effects of narcolepsy in 180 patients from North America, Asia and Europe compared to matched controls", Can J Neurol Sci, 8, pp.299~304 (1981)
- Morgenthaler TI., "Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin", Sleep, 30, pp.1705~1711 (2007)
- Greenhill LL., "Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults", J Am Acad Child Adolesc Psychiatry, 41, pp.26S~49S (2002)
- Littner M., "Practice parameters for the treatment of narcolepsy: an update for 2000", Sleep, 24, pp.451~466 (2000)
- Dauvilliers Y., "Narcolepsy with cataplexy", Lancet, 369, pp.499~511 (2007)
- Kratochvil CJ., "Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit", hyperactivity disorder, 2003, pp.4, 1165~1174
- Thorpy M., "Therapeutic advances in narcolepsy", Sleep Med, 8, pp.427~440 (2007)
- Lammers GJ., "Gammahydroxybutyrate and narcolepsy: a double-blind placebo-controlled study", Sleep, 16, pp.216~220 (1993)
- Hecht M., "Report of a case of immunosuppression with prednisone in an 8- year-old boy with an acute onset of hypocretin-deficiency narcolepsy", Sleep, 26, pp.809~810 (2003)